Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 3OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 9Plasma cell 5Other hematologic neoplasm 5Gastrointestinal 4Breast 4Thoracic 3Myeloid 2Head & Neck 2Gynecologic 2Genitourinary 2Tumor-Agnostic 1Other 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 2Prostatic Neoplasms 1Pathologic Complete Response 1Neoplasms 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 150Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Diphenhydramine × Genitourinary × Clear all
NCT01392183 2021-09-20

Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)

M.D. Anderson Cancer Center

Phase 2 Completed
69 enrolled 15 charts
Genitourinary

Pathologic Complete Response, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT00887640 2014-02-26

Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer

Duke University

Phase 2 Terminated
11 enrolled 9 charts
Genitourinary

Neoplasm Metastasis, Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡